labs show about 5% blasts; a little low on the energy side; stable to a little bit worse; break out a little bit/Rash, pimple like breakout, on face and chest; skin is dry/ Dry flakey skin; white count is up; dry flakey skin; soreness in arm; vomiting/ vomited too many times to count in the last 24 hours; cannot eat; nausea; high blood pressure; dizzy spells; platelets are lower; I breakout a little bit/ Rash, pimple like breakout, on face and chest, that comes and goes; This is a Spontaneous report based on the information received by Pfizer from the Company.(Reference #2020IN007614). A contactable 70-year-old Female consumer reported. A 70-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunization. The patient had surgery to remove the spleen as previously reported. The patient concomitant medications were not reported. The patient underwent lab tests and procedures which included blast cells: 5% on an unspecified date, blood pressure measurement: high on an unspecified date, blood pressure measurement: little bit elevated on an unspecified date, platelet count decreased: lower on an unspecified date, white blood cell count: up on an unspecified date. On an unspecified date, the patient experienced high blood pressure. Upon follow-up, the patient's blood pressure was a little bit elevated and did not stay down as well. The patient experienced dizzy spells, recent labs showed her blasts was at 5%, had a little on the low energy side, and stable to a little bit worse (unspecified since starting Jakafi). Every now and then, the patient break out a little bit and had an overall dry skin. Upon follow-up, on an unknown date, the patient experienced dry flakey skin, rash, pimple like breakout, on face and chest, that comes and goes. She stated that she had clear skin before taking Jakafi. The patient also experienced her white count is up, and platelets are lower and had some soreness in arm. Upon follow-up, on an unspecified date, the patient had developed vomiting. She had vomited too many times to count in the past 24 hours. Due to this, she had missed two doses of Jakafi. She also had nausea and could not eat. The patient Initiated the use of Oral Jakafi (ruxolitinib) 15 mg tablets BID on 15MAY2019 for myelofibrosis. The batch/lot number and expiration date were reported as 9845120, 9845120, 9959039, 1135782 and 30SEP2022, 28FEB2023, 30JUN2023. The outcome of all the events was unknown.   Follow-up was received on 150CT2020 from the consumer (patient) via a specialty pharmacy. Jakafi information was updated. New non-serious events (Recent tabs show about 5% blasts, A little low on the energy side, Stable to a little bit worse, I break out a little bit, Skin is dry, and Dizzy spells) were added. The verbatim of Blood pressure was a little bit elevated and wasn't staying down was added to High blood pressure.    Follow-up was received on 12APR2021 from a consumer (patient) via a specialty pharmacy. Jakafi dosage information was updated. Co-suspect was added as Covid-19 vaccine. New non-serious events (Dry flakey skin, White count is up, Platelets are lower, soreness in arm) were added the verbatim term of Rash, pimple like breakout, on face and chest. that comes and goes was added to the event I break out a little bit. The verbatim term of Dry flakey skin was added to the event Skin is dry.    Follow-up was received on 21APR2021 from a consumer (patient) Via a specialty pharmacy. Additional dosing regimen with lot number and expiration date was added. New non-serious events added: Nausea, vomiting, cannot eat and missed last two doses.   Information about lot/batch number has been requested.